In patients undergoing percutaneous coronary intervention (PCI), glycoprotein IIb/IIIa receptor antagonists significantly reduce the risk of death according to a report in the January 1st issue of the Journal of the American College of Cardiology.
“Several trials have shown that intravenous antagonists of the platelet glycoprotein (GP) IIb/IIIa receptor reduce the incidence of myocardial infarction (MI) and composite cardiac outcomes (death, MI, or revascularization) in patients undergoing PCI,” Dr. John Ioannidis, of the University of Ioannina School of Medicine, Greece, and colleagues note. “However, individual studies have not had adequate powers to examine differences in mortality.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!